Pliant Therapeutics Inc

Pliant Therapeutics Inc has a market capitalization of $72.13 million and a price-to-book ratio of 0.16, indicating a significant discount to its book value. The company's liquidity position is strong, with a current ratio of 16.12 and $114.297 million in cash and equivalents, which is a substantial buffer against its $84.273 million in total liabilities. The debt-to-equity ratio of 0.07 suggests a conservative capital structure with minimal leverage.

The company's profitability metrics are negative, with a return on equity of -10.74% and a return on assets of -9.00%, reflecting ongoing losses. Operating income for the period was -$52.392 million, and net income was -$46.955 million. These figures indicate that the company is not yet generating positive returns for shareholders and is in a development phase typical of biopharmaceutical firms.

Pliant Therapeutics Inc does not disclose specific revenue segments or geographic breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. However, the company's focus on the TGFβ pathway suggests a specialized therapeutic approach, which may limit its market reach but also reduce direct competition.

The company's growth trajectory is uncertain, with no revenue reported in the latest financial snapshot. Analysts have provided a mean price target of $2.67 and a median price target of $3.00, suggesting a potential upside from the current market price of $1.165. However, the mean recommendation of 3.00 (on a scale from 1 to 5) indicates a neutral outlook, with no strong buy ratings and only one buy rating among the analysts surveyed.

The risk assessment for Pliant Therapeutics Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital expenditures were -$1.492 million, and its free cash flow was -$47.934 million, reflecting ongoing investment in operations and development. The risk of dilution is currently low, but the company may need to raise additional capital in the future to fund its operations, which could lead to share dilution.

Recent events and filings do not provide specific details on new product launches or regulatory approvals. The company's focus on the TGFβ pathway and its pipeline of therapeutics for fibrotic and inflammatory diseases suggest that future developments in these areas could significantly impact its financial performance and stock price. Investors should monitor clinical trial results and regulatory decisions for potential catalysts.

Analysts project 145.8% upside to a mean price target of $2.67, significantly above the current market price of $1.09.

The company maintains a strong liquidity position with a current ratio of 12.0, indicating ample short-term assets to cover liabilities.

Operating losses improved by 30.7% year-over-year in FY2026, demonstrating a meaningful reduction in operational cash burn rates.

Free cash flow losses decreased by 30.2% year-over-year in FY2026, suggesting improved capital efficiency in recent operations.

The debt-to-equity ratio of 0.07 ranks above the pharmaceutical cohort median, reflecting a conservative capital structure.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.

Revenue collapsed to zero in FY2025 and FY2026, highlighting a complete lack of commercial product sales or recurring income.

Net losses widened to $210.3 million in FY2025, reflecting significant ongoing operational deficits despite recent improvement trends.

Cash conversion efficiency of 0.64 is below the pharmaceutical cohort median of 0.95, indicating weaker cash generation capabilities.

Operating income +52,4% YoY; Net income +52,6% YoY.

• ▍Operating income +52,4% YoY
• ▍Net income +52,6% YoY
• ▍Free cash flow +53,2% YoY

Operating income +54,4% YoY; Net income +54,5% YoY.

• ▍Operating income +54,4% YoY
• ▍Net income +54,5% YoY
• ▍Free cash flow +55,5% YoY

Revenue $0.00; Operating income +24,8% YoY.

• ▍Revenue $0.00
• ▍Operating income +24,8% YoY
• ▍Net income +22,5% YoY
• ▍Free cash flow +23,9% YoY

Revenue $0.00; Operating income −12,5% YoY.

• ▍Revenue $0.00
• ▍Operating income −12,5% YoY
• ▍Net income −19,6% YoY
• ▍Free cash flow −16,8% YoY

Revenue $0.00; Operating income -$53.3M.

• ▍Revenue $0.00
• ▍Operating income -$53.3M

Revenue $0.00; Operating income -$62.0M.

• ▍Revenue $0.00
• ▍Operating income -$62.0M

Revenue $0.00; Operating income -$60.6M.

• ▍Revenue $0.00
• ▍Operating income -$60.6M

Revenue $0.00; Operating income -$52.4M.

• ▍Revenue $0.00
• ▍Operating income -$52.4M

Revenue $0.00; Operating income +30,7% YoY.

• ▍Revenue $0.00
• ▍Operating income +30,7% YoY
• ▍Net income +29,0% YoY
• ▍Free cash flow +30,2% YoY

Revenue $0.00, −100,0% YoY; Operating income −24,0% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −24,0% YoY
• ▍Net income −30,4% YoY
• ▍Free cash flow −32,2% YoY

Revenue $1.6M, −83,7% YoY; Operating income −44,8% YoY.

• ▍Revenue $1.6M, −83,7% YoY
• ▍Operating income −44,8% YoY
• ▍Net income −30,8% YoY
• ▍Free cash flow −30,1% YoY
• ▍Net margin -10211.1%

Revenue $9.7M, +27,9% YoY; Operating income −30,4% YoY.

• ▍Revenue $9.7M, +27,9% YoY
• ▍Operating income −30,4% YoY
• ▍Net income −26,8% YoY
• ▍Free cash flow −26,2% YoY
• ▍Net margin -1273.3%